PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.90
Bid: 1.80
Ask: 2.00
Change: 0.00 (0.00%)
Spread: 0.20 (11.111%)
Open: 1.90
High: 1.90
Low: 1.90
Prev. Close: 1.90
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EXECUTIVE CHANGE SUMMARY: Harvest Minerals CFO Leaves To Save Cost

Tue, 14th Apr 2020 14:51

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Tuesday and not separately reported by Alliance News:

----------

Harvest Minerals Ltd - David Edghill departs as chief financial officer as part of company cost savings. Executive Chair Brian McMaster will oversee finance function. "The company remains registered in Australia with operations in Brazil and, as such, it has become clear that there are no efficiency gains in having a finance function in the UK," McMaster explained. Additionally, Frank Moxon steps down as non-executive director from June 30 "to pursue other interests".

----------

Dart Group PLC - Appoints Robin Terrell as independent non-executive director, starting immediately. Terrell was chief customer officer for Tesco PLC, having previously served as UK managing director for Amazon.com Inc and also MD of John Lewis Direct.

----------

SVM UK Emerging Fund PLC - Ian Gray hired as a non-executive director, as Tony Puckridge retires, both effective from March 6. Gray is an accountant who also is a non-executive director of DX Group PLC.

----------

Baronsmead Second Venture Trust PLC - Ian Orrock to retire from board on May 1, replaced as senior independent director by Malcolm Groat.

----------

Monks Investment Trust PLC - Hires Claire Boyle as non-executive director from May 1. Worked in equity investment for Robert Fleming Investment Management, American Express Asset Management, and Oxburgh Partners LLP.

----------

ValiRx PLC - George Morris resigns as director immediately.

----------

Idox PLC - Oliver Scott steps down as non-executive director, replaced by Alice Cummings, both immediately. Cummings was chief financial officer of InHealth Group, a healthcare services firm.

----------

Orient Telecoms PLC - Hires Wong Chee Keong as new non-executive chair. Wong has 40 years of experience in the telecommunications industry in Malaysia, Orient noted.

----------

Star Phoenix Group Ltd - Meng YuFeng joins board as nominee of Beijing Sibo Investment Management LP, a large shareholder. Meng has worked in the US, Australia and China in a 30-year career in management and consulting.

----------

Ocean Wilsons Holdings Ltd - Fiona Beck hired as non-executive director from Monday. She was chief executive officer of Southern Cross Cable Network, a submarine fibreoptic cable company connecting New Zealand and Australia to the US.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
21 Feb 2019 12:46

ValiRx Raises GBP500,000 Through Placing To Advance Clinical Trials (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Thursday raised GBP500,000 through a share placing to expand its clinical trial of VAL201, as well as the VAL301 and VAL101 programmes.ValiRx issued a

Read more
31 Jan 2019 13:37

ValiRx Secures Patent For VAL301 Compound In Russia And China

LONDON (Alliance News) - ValiRx PLC on Thursday said it has been granted a patent allowance for its therapeutic compound VAL301 in both Russia and China.The clinical stage biotechnology has

Read more
31 Jan 2019 10:08

ValiRx allowed patents for VAL401 in Russia and China

(Sharecast News) - Clinical-stage biotechnology company ValiRx announced on Thursday that the patent offices of Russia and China had both granted a patent allowance for its pre-clinical therapeutic compound, VAL301, subject to payment of the relevant fees.

Read more
9 Jan 2019 14:57

ValiRx gives NHS Long Term Plan its seal of approval

(Sharecast News) - Clinical stage biotechnology company ValiRx endorsed the Government's new NHS Long Term Plan to improve the quality of patient care and health outcomes on Wednesday.

Read more
9 Jan 2019 11:25

ValiRx Backs New Long-Term UK Government Plan For NHS

LONDON (Alliance News) - Biotechnology firm ValiRx PLC on Wednesday said it endorses the UK government's new NHS long-term plan."The government's recently announced ten-year a

Read more
18 Dec 2018 15:53

VAL401 results accepted for journal publication, says ValiRx

(Sharecast News) - Clinical stage biotechnology company ValiRx announced the acceptance for publication of the first article containing results from the VAL401 clinical trial by the European Journal of Drug Metabolism and Pharmacokinetics on Tuesday.

Read more
10 Dec 2018 11:07

ValiRx releases positive data from recent VAL201 testing

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Monday that independent analysis of VAL201 data showed a "statistically significant" dose dependant response in the reduction of PSA correlated to time on the Phase l/ll clinical trial, involving patients with hormone-sensitive and hormone-resistant prostate cancer.

Read more
10 Dec 2018 10:59

WINNERS & LOSERS SUMMARY: Just Group Jumps 23% On Regulatory Decision

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------NMC up The

Read more
10 Dec 2018 09:06

ValiRx Reports Positive VAL201 Effect On Patients With Prostate Cancer

LONDON (Alliance News) - ValiRx PLC on Monday said an independent analysis of VAL201 showed a positive effect on patients with hormone-sensitive and hormone-resistant prostate cancer.The up

Read more
17 Oct 2018 08:36

ValiRx enters finals stages of clinical trials on VAL201

(Sharecast News) - Clinical stage biotechnology company ValiRx's leading anti-cancer therapeutic has entered the concluding stages of its Phase l/ll clinical trial at University College London Hospital.

Read more
25 Sep 2018 13:23

ValiRx Half Year Loss Widens On Expenses And Share Option Charge

LONDON (Alliance News) - Life science company ValiRx PLC on Tuesday reported a widened loss in the first half of 2018 due to expenses and a sizeable share option charge.The company's to

Read more
6 Sep 2018 11:38

ValiRx Says Clinical Study For Lung Cancer Drug VAL401 Is Approved

LONDON (Alliance News) - Clinical stage biotechnology company ValiRx PLC said Thursday its clinical study report on lung cancer drug VAL401 has been signed and approved by principal in ValiRx were

Read more
6 Sep 2018 09:05

ValiRx enters 'very exciting' phase for cancer therapies

(Sharecast News) - ValiRx told investors on Thursday that its clinical-stage therapeutics had continued to demonstrate "significant potential" for addressing unmet medical needs in oncology.

Read more
14 Jun 2018 11:00

WINNERS & LOSERS SUMMARY: Rolls Royce Flies High With Planned Job Cuts

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - up 2.6%. The jet engine maker said it will cut

Read more
11 May 2018 16:43

Nicholas Slater Increases ValiRx Stake To 4.5% From 2.7% (ALLISS)

LONDON (Alliance News) - ValiRx PLC said Friday Nicholas Slater had almost doubled his stake in life science company, which focuses on cancer treatments, to 4.5% after a transaction on raised his

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.